06-22-2020, 09:55 AM
Looks like the administration is "all in" on a vaccine.
https://www.nytimes.com/2020/06/19/healt...nding.html
That's great if the vaccine works. But if it doesn't, or if it is imperfect, this seems like a short-sighted policy. The dexamethasone trial in the UK showed that drugs are already available that can cut mortality by 20 - 35% (depending on how sick someone is when they come to the hospital). Plus lots of people developing antivirals, monoclonal antibodies, immune modulators, etc. While preventing spread and preventing disease is obviously important and if it can be done effectively will be key for the long-term management of COVID-19, given that this is unlikely to go away entirely, and given the possibility of waning immunity, finding a way to treat people who develop COVID-19 and reduce mortality (and shorten the duration of illness) would seem to be a wise idea.
BC
I should mention that I work for a pharmaceutical company (one whose clinical trials are partly BARDA funded), so I would have a conflict of interest.
https://www.nytimes.com/2020/06/19/healt...nding.html
That's great if the vaccine works. But if it doesn't, or if it is imperfect, this seems like a short-sighted policy. The dexamethasone trial in the UK showed that drugs are already available that can cut mortality by 20 - 35% (depending on how sick someone is when they come to the hospital). Plus lots of people developing antivirals, monoclonal antibodies, immune modulators, etc. While preventing spread and preventing disease is obviously important and if it can be done effectively will be key for the long-term management of COVID-19, given that this is unlikely to go away entirely, and given the possibility of waning immunity, finding a way to treat people who develop COVID-19 and reduce mortality (and shorten the duration of illness) would seem to be a wise idea.
BC
I should mention that I work for a pharmaceutical company (one whose clinical trials are partly BARDA funded), so I would have a conflict of interest.

